Hyperphosphatemia: a novel risk factor for mortality in chronic kidney disease.

Cardiovascular (CV) mortality in chronic kidney disease (CKD) associate with traditional risk factors (1) including dyslipidaemia, diabetes, smoking and left ventricular mass hypertrophy. Furthermore, increasing evidence supports the role of non-traditional risk factors that associate with CV morbidity, especially vascular calcification (2). These risk factors are inflammation and altered mineral metabolism.

[1]  J. Carrero,et al.  Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  A. Schols,et al.  Chronic kidney disease and premature ageing , 2014, Nature Reviews Nephrology.

[3]  M. Vervloet,et al.  Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. , 2014, The lancet. Diabetes & endocrinology.

[4]  M. Wolf,et al.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease , 2014, Nature Reviews Nephrology.

[5]  G. Remuzzi,et al.  Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  J. Carrero,et al.  Use of phosphate-binding agents is associated with a lower risk of mortality. , 2013, Kidney international.

[7]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[8]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[9]  D. Cusi,et al.  Vascular calcification in chronic kidney disease: a changing scenario. , 2011, JN. Journal of Nephrology (Milano. 1992).

[10]  S. Mazzaferro,et al.  The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  J. New,et al.  Serum phosphate and mortality in patients with chronic kidney disease. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[12]  K. Hruska,et al.  The new kidney disease: improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. , 2010, Clinical nephrology.

[13]  M. Wolf,et al.  Forging forward with 10 burning questions on FGF23 in kidney disease. , 2010, Journal of the American Society of Nephrology : JASN.

[14]  S. Mazzaferro,et al.  The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. , 2010, Current vascular pharmacology.

[15]  D. Brancaccio,et al.  Pathogenesis of vascular calcification in chronic kidney disease. , 2005, Kidney international.

[16]  G. Spasovski,et al.  A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. , 2003, Kidney international. Supplement.

[17]  Huiliang Xie,et al.  Mineral metabolites and CKD progression in African Americans. , 2013, Journal of the American Society of Nephrology : JASN.